Cytosolic mislocalization of the RNA binding protein TDP43 and neuronal hyperexcitability are cardinal features of TDP43-related frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Nuclear exclusion and cytosolic deposition of TDP43 are found in over half of those with FTD, and nearly 95% of those with ALS, but the origin of these changes remains unknown. Likewise, neuronal hyperexcitability is a ubiquitous finding in FTD/ALS patients, in vivo and in vitro disease models, yet the cause and consequences of this phenomenon are unclear. Our preliminary data show for the first time an intrinsic connection between TDP43 deposition and neuronal hyperexcitabilty that may play a pivotal part in the neurodegeneration observed in TDP43-related FTD/ALS. Elevated neuronal activity upregulates an uncommon TDP43 isoform that lacks the canonical, low-complexity carboxy-terminus of the protein. Due to its active nuclear export and its ability to bind full-length (fl)TDP43, This shortened (s)TDP43 isoform is actively exported from the nucleus, accumulates in cytosolic aggregates, and sequestrates full-length (fl)TDP43, thereby recapitulating TDP43 pathology in FTD/ALS. Our central goal with this project is to determine the impact of sTDP43 in FTD/ALS pathogenesis, with a long-term objective of defining novel and effective therapeutic strategies targeting TDP43 homeostasis. We will test the hypothesis that sTDP43 drives neurodegeneration in TDP43-related FTD/ALS by three specific aims. First, we will take advantage of an sTDP43-specific antibody that we developed to determine the prevalence and distribution of sTDP43 accumulation in a large cohort of sporadic and familial FTD/ALS cases curated by the University of Michigan Brain Bank. We will also investigate the impact of sTDP43 on RNA homeostasis, and determine the relationship between sTDP43, stress, and stress granules in disease models. Lastly, we will assess the contribution of sTDP43 to neurodegeneration in rodent primary neurons and human induced pluripotent stem cell-derived neurons from patients carrying FTD/ALS-associated C9orf72 hexanucleotide expansion mutations. At the completion of these studies, we will have delineated a unique disease mechanism leading to neurodegeneration in TDP43-related FTD/ALS, and highlighted potential therapeutic approaches focusing on the abnormal activity-dependent production of toxic TDP43 isoforms.
This proposal centers on the impact of atypical, shortened (s) TDP43 isoforms in the pathogenesis of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The studies described here will uncover the prevalence of sTDP43 deposition in sporadic and familial FTD/ALS, illustrate downstream consequences of sTDP43 accumulation for RNA homeostasis, and determine the contribution of sTDP43 to neurodegeneration in FTD/ALS disease models. Our aim is to highlight a heretofore-undiscovered disease mechanism responsible for neurodegeneration in TDP43-related FTD/ALS, paving the way for effective therapeutic approaches that prevent sTDP43 deposition.
